Details of Disease

General Information of Disease (ID: DIS15EA5)

• Disease Name: Ductal carcinoma
• Synonyms: ductal adenocarcinoma; duct adenocarcinoma; ductal carcinoma; duct carcinoma; ductal carcinoma of breast; mammary duct adenocarcinoma; ductal carcinoma of the breast; ductal breast carcinoma; breast ductal carcinoma; ductal breast adenocarcinoma
• Disease Class: 2E65: Breast in situ carcinoma
• Definition: A breast carcinoma arising from the ducts. While ductal carcinomas can arise at other sites, this term is universally used to refer to carcinomas of the breast. Ductal carcinomas account for about two thirds of all breast cancers. Two types of ductal carcinomas have been described: ductal carcinoma in situ (DCIS) and invasive ductal carcinoma. The latter often spreads to the axillary lymph nodes and other anatomic sites. The two forms of ductal carcinoma often coexist.
• Disease Hierarchy:
  DIS3IHTY: Adenocarcinoma
  DISMPHJ0: Breast adenocarcinoma
  DIS15EA5: Ductal carcinoma
• ICD Code:
  ICD-11: ICD-11: 2E65.2
  ICD-10: ICD-10: D05.1
  ICD-9: ICD-9: 233
  Expand ICD-11: 'XH4V32
  Expand ICD-9: 233
• Disease Identifiers:
  MONDO ID: MONDO_0005590
  MESH ID: D044584
  UMLS CUI: C1527349
  MedGen ID: 315942

Drug-Interaction Atlas (DIA) of This Disease

This Disease is Treated as An Indication in 1 Clinical Trial Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Afimoxifene	DMFORDT	Phase 2	Small molecular drug	[1]

Molecular Interaction Atlas (MIA) of This Disease

This Disease Is Related to 15 DTT Molecule(s)

Gene Name	DTT ID	Evidence Level	Mode of Inheritance	REF
PGR	TTUV8G9	Limited	Biomarker	[2]
ASPH	TT2KHP7	Strong	Altered Expression	[3]
CASP6	TTKW4ML	Strong	Biomarker	[4]
CLDN18	TT6PKBX	Strong	Biomarker	[5]
CTSA	TT5NILS	Strong	Biomarker	[6]
MKNK1	TTEZAUX	Strong	Biomarker	[7]
MUC17	TTVO0JU	Strong	Altered Expression	[8]
NODAL	TTK2O1Q	Strong	Biomarker	[7]
NOP2	TTBLG3H	Strong	Biomarker	[9]
PPP3CA	TTA4LDE	Strong	Altered Expression	[10]
RPE65	TTBOH16	Strong	Biomarker	[11]
RPS6KA3	TTUM2ZR	Strong	Altered Expression	[12]
TMBIM6	TT7QSMG	Strong	ModifyingMutation	[13]
TMPRSS2	TT1GM2Z	Strong	Altered Expression	[14]
ZNF224	TT1CDXL	Strong	Altered Expression	[15]

This Disease Is Related to 1 DME Molecule(s)

Gene Name	DME ID	Evidence Level	Mode of Inheritance	REF
HSD17B7	DEDMWFX	Strong	Altered Expression	[16]

This Disease Is Related to 34 DOT Molecule(s)

Gene Name	DOT ID	Evidence Level	Mode of Inheritance	REF
ADAMTS17	OTCFITM9	Strong	Altered Expression	[17]
AFAP1L2	OTJBI0VN	Strong	Altered Expression	[18]
ALDOA	OTWRFTIB	Strong	Altered Expression	[19]
ATL1	OTR2788Y	Strong	Altered Expression	[20]
BCAR1	OTKT2C2N	Strong	Biomarker	[21]
BRD8	OTIKS3PC	Strong	Biomarker	[9]
CKAP4	OTDUC9ME	Strong	Biomarker	[11]
CRLS1	OT7XNL0K	Strong	Biomarker	[22]
CTNND1	OTUMPSHR	Strong	Biomarker	[9]
DSC3	OTYG47F8	Strong	Altered Expression	[23]
EEF1A1	OT00THXS	Strong	Biomarker	[24]
HNRNPU	OTLQN1E2	Strong	Biomarker	[9]
IBSP	OT29944Y	Strong	Biomarker	[25]
IGSF1	OT3XD6U2	Strong	Biomarker	[9]
MGAT5	OTU4DD4G	Strong	Biomarker	[26]
MGAT5B	OT5HP73K	Strong	Biomarker	[26]
MUC3A	OTI4XUDY	Strong	Altered Expression	[8]
MUC7	OTSTMP0X	Strong	Biomarker	[27]
NAA25	OTS3QVF1	Strong	Biomarker	[9]
NOX5	OTHTH59G	Strong	Altered Expression	[28]
NSUN5	OTBN7RS8	Strong	Biomarker	[9]
NT5C3A	OT67KZJA	Strong	Biomarker	[29]
PADI2	OTT40K94	Strong	Altered Expression	[30]
PBXIP1	OTEAAUBY	Strong	Altered Expression	[31]
PDIA6	OT8YBR17	Strong	Altered Expression	[32]
PELP1	OTVXQNOT	Strong	Altered Expression	[33]
PIWIL2	OT1PXQIF	Strong	Altered Expression	[34]
RAB23	OTBAKFBR	Strong	Altered Expression	[35]
RPA2	OTZ54WAF	Strong	Altered Expression	[36]
SIAH2	OTKED2XN	Strong	Altered Expression	[37]
SMARCE1	OTAX4ITH	Strong	Biomarker	[38]
SPINK1	OTSUVAL2	Strong	Altered Expression	[39]
TJP2	OTQUY6BV	Strong	Altered Expression	[40]
TOPBP1	OT6UPZPD	Strong	Altered Expression	[41]

References

• [1] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [2] Association of serum interleukin-10, interleukin-17A and transforming growth factor- levels with human benign and malignant breast diseases.Exp Ther Med. 2018 Jun;15(6):5475-5480. doi: 10.3892/etm.2018.6109. Epub 2018 Apr 30.
• [3] ASPH-notch Axis guided Exosomal delivery of Prometastatic Secretome renders breast Cancer multi-organ metastasis.Mol Cancer. 2019 Nov 7;18(1):156. doi: 10.1186/s12943-019-1077-0.
• [4] Caspase-3 and caspase-6 in ductal breast carcinoma: a descriptive study.Histol Histopathol. 2006 Dec;21(12):1321-9. doi: 10.14670/HH-21.1321.
• [5] Transcriptional regulation of claudin-18 via specific protein kinase C signaling pathways and modification of DNA methylation in human pancreatic cancer cells.J Cell Biochem. 2011 Jul;112(7):1761-72. doi: 10.1002/jcb.23095.
• [6] The prognostic significance of lysosomal protective protein (cathepsin A) in breast ductal carcinoma insitu.Histopathology. 2019 Jun;74(7):1025-1035. doi: 10.1111/his.13835. Epub 2019 Apr 14.
• [7] MNK1/NODAL Signaling Promotes Invasive Progression of Breast Ductal Carcinoma In Situ.Cancer Res. 2019 Apr 1;79(7):1646-1657. doi: 10.1158/0008-5472.CAN-18-1602. Epub 2019 Jan 18.
• [8] Aberrant expression of MUC3 and MUC4 membrane-associated mucins and sialyl Le(x) antigen in pancreatic intraepithelial neoplasia.Pancreas. 2003 Apr;26(3):e48-54. doi: 10.1097/00006676-200304000-00022.
• [9] Further evidence that E-cadherin is not a tumour suppressor gene in invasive ductal carcinoma of the breast: an immunohistochemical study.Histopathology. 2013 Apr;62(5):695-701. doi: 10.1111/his.12066. Epub 2013 Jan 24.
• [10] A Bayesian two-way latent structure model for genomic data integration reveals few pan-genomic cluster subtypes in a breast cancer cohort.Bioinformatics. 2019 Dec 1;35(23):4886-4897. doi: 10.1093/bioinformatics/btz381.
• [11] Immunocytochemical analysis of p63 and 34E12 in fine needle aspiration cytology specimens for breast lesions: a potentially useful discriminatory marker between intraductal papilloma and ductal carcinoma insitu.Cytopathology. 2016 Apr;27(2):108-14. doi: 10.1111/cyt.12244. Epub 2015 Mar 25.
• [12] ER-Mediated Nuclear Sequestration of RSK2 Is Required for ER(+) Breast Cancer Tumorigenesis.Cancer Res. 2018 Apr 15;78(8):2014-2025. doi: 10.1158/0008-5472.CAN-17-2063. Epub 2018 Jan 19.
• [13] Identification of transmembrane proteins as potential prognostic markers and therapeutic targets in breast cancer by a screen for signal sequence encoding transcripts.J Pathol. 2006 Dec;210(4):420-30. doi: 10.1002/path.2071.
• [14] TMPRSS2-ERG gene fusions are infrequent in prostatic ductal adenocarcinomas.Mod Pathol. 2009 Mar;22(3):359-65. doi: 10.1038/modpathol.2008.236. Epub 2009 Jan 16.
• [15] ZNF224, Krppel like zinc finger protein, induces cell growth and apoptosis-resistance by down-regulation of p21 and p53 via miR-663a.Oncotarget. 2016 May 24;7(21):31177-90. doi: 10.18632/oncotarget.8870.
• [16] The stimulation of HSD17B7 expression by estradiol provides a powerful feed-forward mechanism for estradiol biosynthesis in breast cancer cells.Mol Endocrinol. 2011 May;25(5):754-66. doi: 10.1210/me.2010-0261. Epub 2011 Mar 3.
• [17] Sp1 is necessary for gene activation of Adamts17 by estrogen.J Cell Biochem. 2014 Oct;115(10):1829-39. doi: 10.1002/jcb.24855.
• [18] Expression of XB130 in human ductal breast cancer.Int J Clin Exp Pathol. 2015 May 1;8(5):5300-8. eCollection 2015.
• [19] miR-122-5p Inhibits the Proliferation, Invasion and Growth of Bile Duct Carcinoma Cells by Targeting ALDOA.Cell Physiol Biochem. 2018;48(6):2596-2606. doi: 10.1159/000492702. Epub 2018 Aug 17.
• [20] Tenascin C is a prognostic determinant and potential cancer-associated fibroblasts marker for breast ductal carcinoma.Exp Mol Pathol. 2017 Apr;102(2):262-267. doi: 10.1016/j.yexmp.2017.02.012. Epub 2017 Feb 20.
• [21] Ductal carcinoma of the prostate shows a different immunophenotype from high grade acinar cancer.Histopathology. 2013 Jul;63(1):57-63. doi: 10.1111/his.12129. Epub 2013 May 23.
• [22] Mutational Profiling Can Establish Clonal or Independent Origin in Synchronous Bilateral Breast and Other Tumors.PLoS One. 2015 Nov 10;10(11):e0142487. doi: 10.1371/journal.pone.0142487. eCollection 2015.
• [23] Epigenetic silencing of DSC3 is a common event in human breast cancer.Breast Cancer Res. 2005;7(5):R669-80. doi: 10.1186/bcr1273. Epub 2005 Jun 16.
• [24] Contradictory mRNA and protein misexpression of EEF1A1 in ductal breast carcinoma due to cell cycle regulation and cellular stress.Sci Rep. 2018 Sep 17;8(1):13904. doi: 10.1038/s41598-018-32272-x.
• [25] Radioiodination and preclinical evaluation of 4-benzyl-1-(3-[(125)I]-iodobenzylsulfonyl)piperidine as a breast tumor imaging tracer in mouse.Ann Nucl Med. 2017 May;31(4):335-346. doi: 10.1007/s12149-017-1161-8. Epub 2017 Mar 17.
• [26] Lectin histochemistry reveals SNA as a prognostic carbohydrate-dependent probe for invasive ductal carcinoma of the breast: a clinicopathological and immunohistochemical auxiliary tool.Int J Clin Exp Pathol. 2014 Apr 15;7(5):2337-49. eCollection 2014.
• [27] Mucin expression pattern in pancreatic diseases: findings from EUS-guided fine-needle aspiration biopsies.Am J Gastroenterol. 2011 Jul;106(7):1359-63. doi: 10.1038/ajg.2011.22. Epub 2011 Jun 7.
• [28] STAT5A-mediated NOX5-L expression promotes the proliferation and metastasis of breast cancer cells.Exp Cell Res. 2017 Feb 1;351(1):51-58. doi: 10.1016/j.yexcr.2016.12.020. Epub 2016 Dec 26.
• [29] Cytogenetic and comparative genomic hybridization findings in four cases of breast cancer after neoadjuvant chemotherapy.Cancer Genet Cytogenet. 2003 Oct 15;146(2):161-6. doi: 10.1016/s0165-4608(03)00144-4.
• [30] Investigating the expression, effect and tumorigenic pathway of PADI2 in tumors.Onco Targets Ther. 2017 Mar 8;10:1475-1485. doi: 10.2147/OTT.S92389. eCollection 2017.
• [31] Hematopoietic PBX-interacting protein (HPIP) is over expressed in breast infiltrative ductal carcinoma and regulates cell adhesion and migration through modulation of focal adhesion dynamics.Oncogene. 2015 Aug 27;34(35):4601-12. doi: 10.1038/onc.2014.389. Epub 2014 Dec 8.
• [32] PDIA3 and PDIA6 gene expression as an aggressiveness marker in primary ductal breast cancer.Genet Mol Res. 2015 Jun 26;14(2):6960-7. doi: 10.4238/2015.June.26.4.
• [33] Novel estrogen receptor coactivator PELP1/MNAR gene and ERbeta expression in salivary duct adenocarcinoma: potential therapeutic targets.Hum Pathol. 2005 Jun;36(6):670-5. doi: 10.1016/j.humpath.2005.03.016.
• [34] Aberrant Expression of PIWIL1 and PIWIL2 and Their Clinical Significance in Ductal Breast Carcinoma.Anticancer Res. 2018 Apr;38(4):2021-2030. doi: 10.21873/anticanres.12441.
• [35] Inactivation of Rab23 inhibits the invasion and motility of pancreatic duct adenocarcinoma.Genet Mol Res. 2015 Mar 30;14(1):2707-15. doi: 10.4238/2015.March.30.31.
• [36] Autoimmunity to the M(r) 32,000 subunit of replication protein A in breast cancer.Clin Cancer Res. 2002 Mar;8(3):752-8.
• [37] Overexpression of seven in absentia homolog 2 protein in human breast cancer tissues is associated with the promotion of tumor cell malignant behavior in in vitro.Oncol Rep. 2016 Sep;36(3):1301-12. doi: 10.3892/or.2016.4976. Epub 2016 Jul 25.
• [38] Identification of BAF57 mutations in human breast cancer cell lines.Breast Cancer Res Treat. 2006 Jul;98(2):191-8. doi: 10.1007/s10549-005-9149-9. Epub 2006 Mar 15.
• [39] Clinical significance and EZH2, ERG and SPINK1 protein expression in pure and mixed ductal adenocarcinoma of the prostate.Histol Histopathol. 2019 Apr;34(4):381-390. doi: 10.14670/HH-18-046. Epub 2018 Sep 24.
• [40] zo-2 gene alternative promoters in normal and neoplastic human pancreatic duct cells.Int J Cancer. 1999 Oct 29;83(3):349-58. doi: 10.1002/(sici)1097-0215(19991029)83:3<349::aid-ijc10>3.0.co;2-c.
• [41] Expression of TopBP1 in hereditary breast cancer.Mol Biol Rep. 2012 Jul;39(7):7795-804. doi: 10.1007/s11033-012-1622-z. Epub 2012 Apr 28.